11. Predictors of efficacy in patients (pts) with hormone receptor–positive/ human epidermal growth factor receptor 2–negative advanced breast cancer (HR+/HER2− ABC): Subgroup analyses of PALOMA-3. (October 2020) Authors: Rugo, H.; Cristofanilli, M.; Loibl, S.; Harbeck, N.; Demichele, A.; Iwata, H.; Park, Y.H.; Brufsky, A.; Theall, K.Puyana; Huang, X.; McRoy, L.; Bananis, E.; Turner, N.C. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 1 Page Start: S7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. Safety outcomes from monarchE: Phase 3 study of abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer. (April 2021) Authors: Rugo, H.; O'Shaughnessy, J.; Song, C.; Broom, R.; Gumus, M.; Yamashita, T.; San Antonio, B.; Shahir, A.; Zimmermann, A.; Zagouri, F.; Reinisch, M. Journal: Breast Issue: Volume 56(2021)Supplement 1 Page Start: S23 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. The impact of mitotic score versus pleomorphic subtype on disease free survival in invasive lobular carcinoma of the breast. (April 2018) Authors: Mamounas, M.; Wong, J.; Fahrner-Scott, K.; Chen, Y.Y.; Krings, G.; Ewing, C.; Esserman, L.; Alvarado, M.; Rugo, H.; Mukhtar, R. Journal: European journal of cancer Issue: Volume 92(2018)Supplement 3 Page Start: S132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. Treatment selection for patients with low and equivocal ER status. (March 2019) Authors: Rugo, H. Journal: Breast Issue: Volume 44(2019)Supplement 1 Page Start: S7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗